Hep A, NAFLD (Nonalcoholic Fatty Liver Disease)
Conditions
Keywords
Mediterranean Diet,, DASH diet,, Liver Function Test,, Lipid profile,
Brief summary
Participants were assigned into three groups Control group recieving general dietary guidelines, Mediterranean diet intervention group DASH dietary intervention group
Detailed description
Written permission was taken from the ethical board for data collection. After taking informed consent from patients in written form, the researcher used self-administered questionnaire or Performa to gather data. NAFLD patients (both genders) of age 25 to 70 years were included. 1. Screening: The participants eligible under inclusion criteria will be enrolled. The baseline data (weight, height, BMI, waist circumference, LFT's, Lipid profile, blood pressure). The target population between 25-70 years were selected. 2. Allocation: The participants were assigned into three groups; control group was given dietary guidelines followed by medication; one group was given Mediterranean diet (T1) and other group was given DASH diet (T2) along with conventional therapy 3. Follow up: The follow up of patient were conducted monthly, all laboratory test (LFT's, Lipid profile, blood pressure) were conducted on 1st and after 8th week. The baseline and post-test study were compared to test hypothesis.
Interventions
OTHERDietary guidelines for fatty liver
Dietary guidelines for managing fatty liver disease followed by medication for 2 months.
OTHERMediterranean diet
Mediterranean diet plan consists of vegetables, whole grains, and fruit, extra virgin olive oil, nuts, seeds and legumes.
OTHERDASH diet
DASH diet plan consists of antioxidant foods items i.e. fruits and vegetables lean meat and dairy products (low fat dairy products), nuts, grain.
Sponsors
University of Lahore
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
25 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Adults (25-70 years) of both genders with BMI (above 25 kg/m2). * Fatty liver patients with mild to moderate values of Alanine Transaminase (ALT) level range from mild to moderate (30-100U/L) * Fatty liver patients having Aspartate Aminotransferase (AST) level range from mild to moderate (200-600 IU/L). * Fatty liver patients having Gamma-Glutamyl Transferase (GGT level range from mild to moderate(120-300 U/L) were included.
Exclusion criteria
* Lactating and pregnant women were not included. * Patients who are using any kind of medicine. * Adults suffering from critical health conditions, including cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Body Mass Index | 60 days | Body Mass Index (BMI) was computed by dividing weight in kilograms by the square of height in meters (kg/m2). |
| Liver Function Test | 60 days | The blood test was used to measure the serum concentrations of ALT, AST, and GGT. Following an overnight fast, 10 ml of venous blood was collected from participants both at baseline and post-intervention. |
Countries
Pakistan
Outcome results
None listed